to inhibit the binding of PD‐L1 is substantially reduced for glycosylation‐deficient PD‐1. These results increase our understanding of how glycosylation affects the activity of PD‐1‐specific MAbs during immune checkpoint therapy. PD‐1是一种高度糖基化的抑制性受体,主要在T细胞上表达。用单克隆抗...
CRI分析了I/O药物的6个关键类别,包括针对T细胞的免疫调节剂(T-cell targeted immunomodulator)、针对其他靶点的免疫调节剂(other immunomodulator)、癌症疫苗(cancer vaccine)、细胞基因疗法(cell therapy)、溶瘤病毒(oncolytic virus)、靶向CD3的双特异性单克隆抗体(CD3-targeted bispecific mab)等。在这些类别中,2017年...
Henlius' anti-PD-1 mAb MRCT achieved 15.38 months OS in first-line treatment of SCLC, reducing the risk of death by 38% of the overall population Shanghai, China, December 17th, 2021 – Shanghai Henlius Biotech, ...
[1] Lin S, Pan J, Han L, et al. Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin. Radiother Oncol. 2014 Mar;110(3):385-...
美国FDA已经批准PD-1单抗6款(pembrolizumab、nivolumab、avelumab、cemiplimab、dostarlimab、retifanlimab),PD-1单抗2款(atezolizumab、durvalumab);中国自主研发上市PD-1单抗9款(camrelizumab、sintilimab、tislelizumab、toripalimab、penpulimab、cadonilimab、serplulimab、zimberelimab、pucotenlimab),PD-L1...
CRI分析了I/O药物的6个关键类别,包括针对T细胞的免疫调节剂(T-cell targeted immunomodulator)、针对其他靶点的免疫调节剂(other immunomodulator)、癌症疫苗(cancer vaccine)、细胞基因疗法(cell therapy)、溶瘤病毒(oncolytic virus)、靶向CD3的双特异性单克隆抗体(CD3-targeted bispecific mab)等。在这些类别中,2017年...
[14] Sun H -C,Zhu X -D,Huang C, et al.Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study[J].Journal of Clinical Oncology, 2020. [15] Yang Y,Li Q.An exploratory study of sorafenib plus toripalimab for ...
trastuzumab as a marker of trastuzumab benefit. Br. J. Cancer 119, 1487–1494 (2018).14. Stagg, J. et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108, 7142–7147 (2011).
重回PD-1“出海”赛道的特瑞普利单抗（toripalimab），即将迎来获批上市前的关键一步。日前，Coherus BioSciences,Inc.（以下简称“Coherus”）发布2022年第四季度及全年业绩报告，其中指出，美国食品药品监督管理局（以下简称“FDA”）计划2023年第二季度对特瑞普利单抗中国生产基地进行必要的检查，这是FDA对该药物用于...
根据NCCN指南,对于具有敏感基因突变的非小细胞肺癌患者,特别是EGFR敏感突变的患者,不建议使用PD-1 / PD-L1抑制剂,因为存在致癌基因时,免疫单药治疗缺乏益处还有可能出现超进展。 2 优先靶向治疗,生存获益有限 初治EGFR阳性且PD-L1高表达的患者,靶向获益不明显,且预后较差。